Intermediate for Daclatasvir. Daclatasvir (trade name: Daklinza) is a medication used in combination with other medications to treat hepatitis C (HCV). Daclatasvir stops HCV viral RNA replication and protein translation by directly inhibiting HCV protein NS5A which is critical for HCV viral transcription and translation. Daclatasvir has been approved by the U.S Food and Drug Administration on June 24, 2015.


Product Name:                  4,4'-Diacetylbiphenyl

Synonyms:                         N/A

CAS Number:                     787-69-9

Molecular Weight:            238.2854

Molecular Formula:          C16H14O2

Purity (HPLC):                     ≥95%

Shipping Conditions:         Room temperature.

Storage Conditions:           Refrigerated.

Regulatory Statement:      For Research Use Only.

SMILES:                               CC(=O)c1ccc(cc1)c1ccc(cc1)C(=O)C


  • $69.00
  • Ex Tax: $69.00

Available Options